Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, et al. ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad191.
Google Scholar
Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139(23):2642–53.
Google Scholar
McEvoy JW, Daya N, Tang O, Fang M, Ndumele CE, Coresh J, Christenson RH, Selvin E. High-sensitivity troponins and mortality in the general population. Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad328.
Google Scholar
Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J. 2014;35(34):2303–11.
Google Scholar
Sattar N, Mills NL, Porteous D, Campbell A, Woodward M, Welsh C, Padmanabhan S, Hayward C, McConnachie A, Boachie C, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clin Chem. 2018;64(11):1607–16.
Google Scholar
Kimenai DM, Martens RJH, Kooman JP, Stehouwer CDA, Tan FES, Schaper NC, Dagnelie PC, Schram MT, van der Kallen CJH, Sep SJS, et al. Troponin I and T in relation to cardiac injury detected with electrocardiography in a population-based cohort—the maastricht study. Sci Rep. 2017;7(1):6610.
Google Scholar
Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Rosjo H, Saltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61(12):1240–9.
Google Scholar
de Fay Lavallaz J, Prepoudis A, Wendebourg MJ, Kesenheimer E, Kyburz D, Daikeler T, Haaf P, Wanschitz J, Loscher WN, Schreiner B, et al. Skeletal muscle disorders: a noncardiac source of cardiac troponin T. Circulation. 2022;145(24):1764–79.
Google Scholar
Tang O, Matsushita K, Coresh J, Ndumele C, McEvoy JW, Sharrett AR, Hoogeveen R, Ballantyne CM, Selvin E. High-sensitivity cardiac troponin I and T for cardiovascular risk stratification in adults with diabetes. Diabetes Care. 2020;43(10):e144–6.
Google Scholar
Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015;61(2):368–78.
Google Scholar
Zelniker TA, Wiviott SD, Mosenzon O, Goodrich EL, Jarolim P, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding J, et al. Association of cardiac biomarkers with major adverse cardiovascular events in high-risk patients with diabetes: a secondary analysis of the DECLARE-TIMI 58 trial. JAMA Cardiol. 2023. https://doi.org/10.1001/jamacardio.2023.0019.
Google Scholar
Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704–12.
Google Scholar
Centers for Disease Control and Prevention/National Center for Health Statistics. Questionnaires, Datasets, and Related Documentation for NHANES 1999–2000. https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=1999. Accessed July 10, 2023.
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers. High-Sensitivity Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer v092021. 2022. https://ifcc.web.insd.dk/media/479205/highsensitivity-cardiac-troponin-i-and-t-assay-analyticalcharacteristics-designated-by-manufacturerv092021-3.pdf. Accessed July 10, 2023.
McEvoy JW, Tang O, Wang D, Ndumele CE, Coresh J, Christenson RH, Selvin E. Myocardial injury thresholds for 4 high-sensitivity troponin assays in U.S. adults. J Am Coll Cardiol. 2023;81(20):2028–39.
Google Scholar
Centers for Disease Control and Prevention/National Center for Health Statistics. High-sensitivity cardiac troponins (Surplus) (SSTROP_A). https://wwwn.cdc.gov/Nchs/Nhanes/1999-2000/SSTROP_A.htm. Accessed July 10, 2023.
Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed July 09, 2023.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, et al. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-s40.
Google Scholar
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–49.
Google Scholar
Aakre KM, Saenger AK, Body R, Collinson P, Hammarsten O, Jaffe AS, Kavsak P, Omland T, Ordonez-Lianos J, Apple FS. Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers. Clin Chem. 2022;68(8):1022–30.
Google Scholar
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169(1):20–9.
Google Scholar
Rubin J, Matsushita K, Ballantyne CM, Hoogeveen R, Coresh J, Selvin E. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012;59(5):484–9.
Google Scholar
Myhre PL, Lyngbakken MN, Berge T, Roysland R, Aagaard EN, Pervez O, Kvisvik B, Brynildsen J, Norseth J, Tveit A, et al. Diagnostic thresholds for pre-diabetes mellitus and diabetes mellitus and subclinical cardiac disease in the general population: data from the ACE 1950 study. J Am Heart Assoc. 2021;10(11):e020447.
Google Scholar
Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, Hoogeveen RC, Sharrett AR, Ballantyne CM, Coresh J. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374–82.
Google Scholar
Nguyen K, Fan W, Bertoni A, Budoff MJ, Defilippi C, Lombardo D, Maisel A, Szklo M, Wong ND. N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin as markers for heart failure and cardiovascular disease risks according to glucose status (from the multi-ethnic study of atherosclerosis [MESA]). Am J Cardiol. 2020;125(8):1194–201.
Google Scholar
Tang O, Daya N, Matsushita K, Coresh J, Sharrett AR, Hoogeveen R, Jia X, Windham BG, Ballantyne C, Selvin E. Performance of high-sensitivity cardiac troponin assays to reflect comorbidity burden and improve mortality risk stratification in older adults with diabetes. Diabetes Care. 2020;43(6):1200–8.
Google Scholar
Bluro IM, Nardi MA, De Miguel R, Fernández M, Rolando JY, Abraham Fóscolo MM, Denaday LR, Candenas N, Cagide AM, Pizarro R, et al. Distribution and prognostic value of high-sensitive troponin T measurement in patients with type 2 diabetes without cardiovascular disease. Endocrinol Diabetes Nutr. 2021;68(5):321–8.
Google Scholar
Krintus M, Kozinski M, Boudry P, Lackner K, Lefevre G, Lennartz L, Lotz J, Manysiak S, Shih J, Skadberg O, et al. Defining normality in a European multinational cohort: critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. Int J Cardiol. 2015;187:256–63.
Google Scholar
Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9):989–98.
Google Scholar
Witkowski M, Wu Y, Hazen SL, Tang WHW. Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes. Cardiovasc Diabetol. 2021;20(1):171.
Google Scholar
Sabbatinelli J, Giuliani A, Bonfigli AR, Ramini D, Matacchione G, Campolucci C, Ceka A, Tortato E, Rippo MR, Procopio AD, et al. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study. Cardiovasc Diabetol. 2022;21(1):180.
Google Scholar
Echouffo-Tcheugui JB, Musani SK, Bertoni AG, Correa A, Fox ER, Mentz RJ. Patients phenotypes and cardiovascular risk in type 2 diabetes: the jackson heart study. Cardiovasc Diabetol. 2022;21(1):89.
Google Scholar
Welsh P, Woodward M, Hillis GS, Li Q, Marre M, Williams B, Poulter N, Ryan L, Harrap S, Patel A, et al. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care. 2014;37(8):2202–10.
Google Scholar
Jende JME, Groener JB, Kender Z, Hahn A, Morgenstern J, Heiland S, Nawroth PP, Bendszus M, Kopf S, Kurz FT. Troponin T parallels structural nerve damage in type 2 diabetes: a cross-sectional study using magnetic resonance neurography. Diabetes. 2020;69(4):713–23.
Google Scholar
Bojer AS, Sorensen MH, Vejlstrup N, Goetze JP, Gaede P, Madsen PL. Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):184.
Google Scholar
Hicks CW, Wang D, McDermott K, Matsushita K, Tang O, Echouffo-Tcheugui JB, McEvoy JW, Christenson RH, Selvin E. Associations of cardiac biomarkers with peripheral artery disease and peripheral neuropathy in US adults without prevalent cardiovascular disease. Arterioscler Thromb Vasc Biol. 2023;43(8):1583–91.
Google Scholar
Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381–7.
Google Scholar
Waqas K, Chen J, Trajanoska K, Ikram MA, Uitterlinden AG, Rivadeneira F, Zillikens MC. Skin autofluorescence, a noninvasive biomarker for advanced glycation end-products, is associated with sarcopenia. J Clin Endocrinol Metab. 2022;107(2):e793–803.
Google Scholar
Yoshioka K. Skin autofluorescence is associated with high-sensitive cardiac troponin T, a circulating cardiac biomarker, in Japanese patients with diabetes: a cross-sectional study. Diab Vasc Dis Res. 2018;15(6):559–66.
Google Scholar
Sanganalmath SK, Dubey S, Veeranki S, Narisetty K, Krishnamurthy P. The interplay of inflammation, exosomes and Ca(2+) dynamics in diabetic cardiomyopathy. Cardiovasc Diabetol. 2023;22(1):37.
Google Scholar
Giannitsis E, Katus HA. Concerns about the stability of hsTnI assay after 20 years of storage. J Am Coll Cardiol. 2017;69(22):2772–3.
Google Scholar
